Core Viewpoint - Haier Biomedical demonstrated strong resilience in its development, achieving a revenue of 2.33 billion yuan in 2025, with a year-on-year growth of 2.0% and a fourth-quarter revenue growth of 13.1% [2]. Group 1: Overseas Development - Haier Biomedical's overseas revenue reached 840 million yuan in 2025, marking a year-on-year growth of 17.9% and accounting for 36% of total revenue, an increase of 5 percentage points from 2024 [4]. - The company has seen a compound annual growth rate of over 20% in overseas revenue from 2016 to 2024, with notable growth in Europe (16.0%), Asia-Pacific (26.0%), Americas (12.2%), and Africa (17.8%) [4]. - The Eco-Drive technology developed by the company has improved efficiency by 30%, achieving the highest energy efficiency in the industry [4]. Group 2: Innovation and New Industries - New industries contributed 48.5% of total revenue in 2025, with a year-on-year growth of 8.8%, particularly driven by the smart medication sector, which grew by 18.8% [7]. - The blood technology sector also maintained double-digit growth at 14.8%, with a market share exceeding 50% in plasma collection solutions [8]. - The laboratory sector achieved a growth of 4.9%, with key products maintaining leading market shares among domestic brands [9]. Group 3: AI and Technological Advancements - AI technology has become a significant driver for Haier Biomedical, with AI-related revenue accounting for 15% of total revenue in 2025, an increase of 2.5 percentage points from 2024 [12]. - The company launched 11 new products in 2025, including fully automated cell culture workstations and automated tumor liquid robots, showcasing its commitment to innovation [11]. - Collaborations with research institutions have led to the development of advanced solutions, enhancing the company's technological capabilities and market position [11].

Core Insights - The China International Import Expo (CIIE) serves as a significant platform for showcasing innovation and collaboration, with Haier Biomedical presenting multiple cutting-edge technologies and solutions this year [1][3] Group 1: Breakthrough Technologies and Innovations - Haier Biomedical introduced the first domestic ultra-speed centrifuge capable of exceeding 100,000 RPM, filling a gap in high-end centrifuge equipment in China and positioning the country as the third globally to master this technology [3] - The company also launched a fully automated closed cell expansion system, designed for cell culture and exosome preparation, which enhances efficiency and reduces contamination risks [3] - The AI-driven low-temperature storage management solution, based on original -86°C NAIT recognition technology, streamlines sample management processes, significantly improving operational efficiency for researchers [5] Group 2: Green Development and Sustainability - Haier Biomedical emphasizes green development, showcasing energy-efficient products that save 50% in daily electricity consumption compared to traditional models, equating to an annual saving of 2,843 kWh [6] - The company has established a comprehensive green value chain covering procurement, manufacturing, logistics, and product lifecycle, with 44 product models receiving Energy Star certification [6] - Haier Biomedical's solar-powered vaccine refrigerators and mobile laboratories have been deployed in over 80 countries along the Belt and Road Initiative, contributing to the "Green Silk Road" [6] Group 3: Global Market Expansion - The company has adopted a localized strategy, with products and solutions reaching over 160 countries and benefiting more than 100 million users globally [7][8] - Haier Biomedical's participation in the CIIE highlights its commitment to high-level openness and innovation in the life sciences sector, with a focus on ecological integration and resource efficiency [8]

Core Insights - The company has launched China's first ultra-speed centrifuge capable of exceeding 100,000 RPM, which can be widely used in virus separation, exosome extraction, and nanomedicine research [1] - The company emphasizes three innovation concepts: original technology innovation, clinical value innovation, and ecological cooperation innovation, aiming to provide practical support for scientific research and clinical practice [1] - The company has introduced an intelligent management solution for biological sample libraries, enhancing management efficiency significantly [1] Group 1 - The ultra-speed centrifuge represents a significant technological advancement, marking the company as the first in China to master this technology [1] - The company showcased over 30 new achievements at the exhibition, with more than 60% being first-time presentations, demonstrating its ongoing commitment to technological advancement [1] - The intelligent management solution for biological samples allows for precise tracking and rapid inventory checks, improving research management efficiency [1] Group 2 - The company is committed to green development, with its self-developed ultra-low temperature storage boxes saving 50% in daily electricity consumption compared to traditional equipment [2] - The company has developed solar-powered vaccine refrigerators and mobile laboratories, which have been implemented in over 80 countries and regions along the Belt and Road Initiative [2] - The company aims to leverage the platform of the expo to integrate into global public health governance and promote Chinese health solutions internationally [2]

Group 1 - The core point of the article highlights that Haier Biomedical has launched China's first ultra-speed centrifuge capable of exceeding 100,000 RPM, which can be widely used in virus separation, exosome extraction, and nanomedicine research [1] - The company emphasizes its commitment to technological innovation, clinical value innovation, and ecological cooperation, aiming to ensure that research results are practical and can be upgraded [1] - Haier Biomedical has showcased over 30 new achievements at the exhibition, with more than 60% being first-time presentations, demonstrating its ongoing capability to advance at the forefront of technology [1] Group 2 - The company has introduced the "Edmond Biological Sample Intelligent Management Solution," which enables intelligent management of biological samples from storage to retrieval, significantly improving research management efficiency [1] - Haier Biomedical's self-developed ultra-low temperature storage boxes can save 50% in daily electricity consumption compared to traditional equipment, equating to an annual savings of 2,843 kWh per unit [2] - The company has developed solar-powered vaccine refrigerators and mobile laboratories, which have been applied in over 80 countries and regions involved in the Belt and Road Initiative, contributing to the construction of a "green silk road" [2]

当前，AI与医疗健康的融合已从技术探索迈向规模化应用，推动行业进入数智化转型新阶段。4月8日-11日， 在 第91届中国国际医疗器械(春季)博览会 (以下简称"CMEF") 上，盈康一生旗下 海尔生物医疗 以"Ai在海 尔，因Ai盈康 "为主题，携多个"AI+智慧场景"和15大明星产品重磅亮相。 从AI+智慧样本库、AI+智慧科研，到AI+智慧用药、AI+智慧疫苗接种、AI+智慧血液管理，海尔生物医疗以新 科技、新场景、新生态，不仅为行业带来一场生命科学与医疗创新+AI的生态成果盛宴，也为产业重构带来了 未来想象空间。 # 逐"绿"向"智"，构建生命科学研究新范式 在可持续发展与智能化转型浪潮下，绿色科技与AI技术正重构生命科学产业范式，加速推进全链条数智化进 程。此次CMEF上，海尔生物医疗立足 样本高质量保藏管理和医院临床干细胞研究 ，为高校、科研机构、医 院、药企等用户带来了 一站式样本库全生命周期解决方案、可按需定制的智慧实验室场景解决方案 等，助力 生命科学研究和前沿医学进步。 在AI+智慧样本库展区，海尔生物医疗立足高质量样本库建设需求，带来了 一站式样本库全生命周期解决方案 和4大首发新品。 基 ...